Cystoid macular oedema drug begins testing
IBI-20089, a drug candidate for the treatment of cystoid macular oedema (CME), has completed patient enrollment for initial clinical testing, according to the drug's manufacturer, Icon Bioscience Inc (IBI).
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Recent Videos
Related Content
